{"id":"W4306319940","doi":"10.1016/j.htct.2022.09.415","title":"A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3","year":2022,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Multiple myeloma; Cohort; Refractory (planetary science); Antibody; Oncology; Immunology; Cancer; Immunotherapy; Chimeric antigen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322023,0.001751766,0.001405302,0.0004065944,0.0004293656,0.0008296699,0.0008145254,0.001105491,0.004210011],"category_scores_gemma":[0.0009095268,0.0005283492,0.00092581,0.0003323659,0.0007446968,0.0008287131,0.0003982028,0.002652724,0.0009981674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008460085,"about_ca_system_score_gemma":0.001407302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009218811,"about_ca_topic_score_gemma":0.002156436,"domain_scores_codex":[0.9996556,0.0001809391,0.00001232728,0.00006537956,0.00002773492,0.00005804031],"domain_scores_gemma":[0.9995635,0.00006774228,0.00008252325,0.00004091159,0.00002533049,0.0002198883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.844364,0.05105413,0.003993399,0.0004446204,0.000683061,0.0002815064,0.0002392632,0.001722245,0.03348275,0.0003155824,0.004590668,0.05882876],"study_design_scores_gemma":[0.7627808,0.2241163,0.006586759,0.00001957866,0.0002639545,0.0002402201,0.00003259276,0.001269322,0.002322755,0.000269152,0.002077669,0.00002080402],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905571,0.001169077,0.0006437475,0.0005627273,0.0001213091,0.003123091,0.001489153,0.000110418,0.002223358],"genre_scores_gemma":[0.982819,0.001342426,0.002269462,0.001295293,0.0002641061,0.004399481,0.00382266,0.00005332879,0.003734293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004210011,"threshold_uncertainty_score":0.01408392,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02203625195843619,"score_gpt":0.307113675771095,"score_spread":0.2850774238126588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}